** Shares of AnaptysBio ANAB.O fall as much as 38.5% to an over one-year low of $14.20
** Stock set for worst day since Nov 2019, if losses hold
** Co says it will discontinue development of its eczema drug ANB032 after it failed to meet the goals of a mid-stage trial
** Drug did not meet the main goal of a proportion of patients achieving an at least 75% improvement of symptoms on an eczema severity index
** ANAB will focus on the rest of its autoimmune portfolio, which includes drugs for rheumatoid arthritis and a type of inflammatory bowel disease - CEO
** Up to last close, stock down 30.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。